Jimscaline
From Wikipedia, the free encyclopedia
Jump to: navigation, search
Clinical data | |
---|---|
Routes of administration |
Oral |
ATC code | none |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | 890309-57-6 N |
PubChem | CID 11673493 |
ChemSpider | 9848222 N |
Chemical and physical data | |
Systematic (IUPAC) name: (R)-(2,3-dihydro-4,5,6-trimethoxy-1H-inden-1-yl)aminomethane
|
|
3D model (Jmol) | Interactive image |
Formula | C13H19NO3 |
Molar mass | 237.294 g/mol |
|
|
|
|
NY (what is this?) (verify) |
Jimscaline (C-(4,5,6-trimethoxyindan-1-yl)methanamine) is a conformationally-restricted derivative of the cactus-derived hallucinogen mescaline, which was discovered in 2006 by a team at Purdue University led by David E. Nichols. It acts as a potent agonist for the 5-HT2A and 5-HT2C receptors with the more active (R)-enantiomer having a Ki of 69 nM at the human 5-HT2A receptor, and around three times the potency of mescaline in drug-substitution experiments in animals.[1] This discovery that the side chain of the phenethylamine hallucinogens could be constrained to give chiral ligands with increased activity then led to the later development of the super-potent benzocyclobutene derivative TCB-2.[2][3]
See also[edit]
References[edit]
- ^ McLean TH, Chambers JJ, Parrish JC, Braden MR, Marona-Lewicka D, Kurrasch-Orbaugh D, Nichols DE (13 July 2006), "C-(4,5,6-trimethoxyindan-1-yl)methanamine: a mescaline analogue designed using a homology model of the 5-HT2A receptor.", Journal of Medicinal Chemistry, 49 (14): 4269–74, doi:10.1021/jm060272y, PMID 16821786 CS1 maint: Uses authors parameter (link)
- ^ McLean TH, Parrish JC, Braden MR, Marona-Lewicka D, Gallardo-Godoy A, Nichols DE (21 September 2006), "1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists.", Journal of Medicinal Chemistry, 49 (19): 5794–803, doi:10.1021/jm060656o, PMID 16970404 CS1 maint: Uses authors parameter (link)
- ^ Michael Robert Braden PhD. Towards a biophysical understanding of hallucinogen action. Purdue University 2007.
This Hallucinogen-related article is a stub. You can help Wikipedia by expanding it. |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Phenethylamines |
|
---|---|
Amphetamines |
|
Phentermines |
|
Cathinones |
|
Phenylisobutylamines | |
Phenylalkylpyrrolidines | |
Catecholamines (and close relatives) |
|
Miscellaneous |
|
Hidden categories:
- CS1 maint: Uses authors parameter
- Articles with changed CASNo identifier
- Articles with changed ChemSpider identifier
- Chemical articles having calculated molecular weight overwritten
- Articles with changed InChI identifier
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without UNII source
- Drugboxes which contain changes to verified fields
- All stub articles